DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes, and for use by healthcare providers in hospitals. On March 24, 2006, it received approval from the Untied States Food and Drug Administration (FDA) for its first product, the STS, designed for up to three days of continuous use. On May 31, 2007, it received approval from the FDA for its second-generation continuous glucose monitoring system, the SEVEN, designed for up to seven days of continuous use. As part of its commercialization of the SEVEN, the Company discontinued sales of its STS three-day durable system during the year ended December 31, 2007, and discontinued the sale of its three-day sensors during the year ended December 31, 2008. On February 13, 2009, it received approval from the FDA for its third-generation continuous glucose monitoring system, which it seeks to brand as SEVEN PLUS.